Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran

Keyphrases

• Alanine Aminotransferase 9%
• Antithrombotic Agents 100%
• Clinical Development 9%
• Days of Treatment 9%
• Enoxaparin 27%
• Hip Fracture Surgery 9%
• Hip Replacement 9%
• Liver Enzymes 9%
• Liver Injury 9%
• Liver Toxicity 27%
• Oral Direct Thrombin Inhibitor 9%
• Postoperative Day 9%
• Premature Termination 9%
• Prolonged Administration 18%
• Relative Efficacy 9%
• Safety Assessment 100%
• Study Termination 9%
• Treatment Withdrawal 9%
• Upper Normal Limit 9%
• Venous Thromboembolism Prevention 9%
• Ximelagatran 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Alanine Aminotransferase 9%
• Anticoagulant Agent 100%
• Enoxaparin 27%
• Hepatotoxicity 27%
• Hip Fracture 9%
• Liver Enzyme 9%
• Liver Injury 9%
• Prematurity 9%
• Safety Assessment 100%
• Symptom 9%
• Thrombin Inhibitor 9%
• Venous Thromboembolism 9%
• Ximelagatran 100%